<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        290-186-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NEGAFEN 250 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TERBINAFINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        68.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        D01BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Terbinafine, the active ingredient of <strong>Negafen</strong> tablets, is an antifungal medicine.</p><p><strong>Negafen </strong>tablets are indicated for the treatment of the following fungal infections:</p><p>-&nbsp;&nbsp;&nbsp; Onychomycoses (fungal infection of the nails) due to the infection with dermatophytes (<em>Tinea unguium</em>).</p><p>-&nbsp;&nbsp;&nbsp; Extensive, severe ringworm infections (<em>Tinea corporis, Tinea cruris and Tinea pedis</em>).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Children should not normally be given Negafen tablets. </strong></p><p><strong>Do not take Negafen if:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; You are allergic (hypersensitive) to terbinafine or any of the other ingredients of these tablets (See Section no. 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; You have severe liver or kidney problems.</p><p><strong>Talk to your doctor if: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; You have psoriasis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; You have systemic lupus erythematosis (SLE).</p><p><strong>Taking other medicines: </strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>Some other medicines may influence the use of <strong>Negafen</strong> or vice versa.</p><p><strong>Tell your doctor if you are taking any of the following: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Rifampicin )medicine for infections(</p><p>&middot;&nbsp;&nbsp;&nbsp; Cimetidine )medicine for gastric problems such as indigestion or ulcer)</p><p>&middot;&nbsp;&nbsp;&nbsp; Antidepressants including tricyclic antidepressants, SSRIs (selective serotonin reuptake inhibitors), or MAOIs (monoamine oxidase inhibitors)</p><p>&middot;&nbsp;&nbsp;&nbsp; Oral contraceptives (as irregular periods and breakthrough bleeding may occur in some female patients)</p><p>&middot;&nbsp;&nbsp;&nbsp; Beta-blockers or anti-arrhythmics for heart problems</p><p>&middot;&nbsp;&nbsp;&nbsp; Warfarin (used to thin the blood)</p><p>&middot;&nbsp;&nbsp;&nbsp; Medicines to treat heart problems (e.g. propafenone, amiodarone)</p><p>&middot;&nbsp;&nbsp;&nbsp; Ciclosporin, a medicine used to control your body&rsquo;s immune system in order to prevent rejection of transplanted organs</p><p>&middot;&nbsp;&nbsp;&nbsp; Medicines used to treat fungal infections (e.g. fluconazole, ketoconazole)</p><p>&middot;&nbsp;&nbsp;&nbsp; Medicines used to treat cough (e.g. dextromethorphan)</p><p>&middot;&nbsp;&nbsp;&nbsp; Caffeine</p><p>You should have blood tests before and during treatment with <strong>Negafen</strong> to monitor your liver function.</p><p><strong>Pregnancy and Breast-feeding:</strong></p><p>If you are pregnant or planning to become pregnant, speak to your doctor before taking <strong>Negafen</strong>.</p><p>Do not take this medicine if you are breast-feeding as terbinafine can pass into breast milk.</p><p><strong>Driving and using machines: </strong></p><p>Some people have reported feeling dizzy or giddy while they are taking <strong>Negafen</strong>. If you feel like this you should not drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The doctor will decide what dose of <strong>Negafen</strong> you should take. Always take the <strong>Negafen</strong> exactly as your doctor has told you to. &nbsp;If you are not sure, ask your doctor or pharmacist.</p><p><strong>The usual dose for adults, including the elderly, is 250mg once daily. </strong></p><p>The duration of treatment depends on the type, extent and severity of infection, as follows:</p><p><em>Onychomycoses:</em> 250mg once daily for 6 weeks (for fingernail infections) to 12 weeks (for toenail infections). Some toenail infections may require longer therapy, depending on the extent of the infection.</p><p>Tinea pedis: 250mg once daily for 2 - 6 weeks.</p><p>Tinea cruris: 250mg once daily for 2 - 4 weeks.</p><p>Tinea corporis: 250mg once daily for 4 weeks.</p><p><strong><u>Notes:</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; If your kidneys are not working very well, your doctor may reduce the dose of <strong>Negafen</strong> you take.</p><p>&middot;&nbsp;&nbsp;&nbsp; Swallow the tablets whole with a glass of water.</p><p><strong>If you forget to take Negafen: </strong></p><p>If you forget to take <strong>Negafen</strong>. Take a dose as soon as you remember, then continue to take your medicine at the usual times. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you take more Negafen than you should: </strong></p><p>If you take more <strong>Negafen</strong> than you should, talk to a doctor or go to a hospital straight away.</p><p><strong>If you stop taking Negafen: </strong></p><p>Do not stop the treatment. Contact your doctor or pharmacist before stopping.</p><p><strong>If you have any further questions on the use of this product, ask your doctor or pharmacist. </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines <strong>Negafen </strong>can cause side effects, although not everyone will get them.</p><p>Any side effects are usually mild or moderate and don&rsquo;t last for too long.</p><p><strong><u>Some side effects can be serious: </u></strong></p><p>Stop taking the <strong>Negafen </strong>and tell your doctor immediately if you notice any of the following rare symptoms:</p><p>&middot;&nbsp;&nbsp;&nbsp; Yellowing of your skin or eyes. Unusually dark urine or pale faeces, unexplained persistent nausea, stomach problems, loss of appetite or unusual tiredness or weakness (this may indicate liver problems), increase in liver enzymes which may be noted on a blood test result.</p><p>&middot;&nbsp;&nbsp;&nbsp; Severe skin reactions including rash, light sensitivity, blistering or wheals.</p><p>&middot;&nbsp;&nbsp;&nbsp; Weakness, unusual bleeding, bruising, abnormal pale skin, unusual tiredness, or weakness or breathlessness on exertion or frequent infections (this may be a sign of blood disorders).</p><p>&middot;&nbsp;&nbsp;&nbsp; Difficulty breathing, dizziness, swelling mainly of the face and throat, flushing, crampy abdominal pain, stiffness, rash, fever or swollen/enlarged lymph nodes (possible signs of severe allergic reactions).</p><p>&middot;&nbsp;&nbsp;&nbsp; Symptoms such as rash, fever, itching, tiredness or if you notice appearance of purplish spots under the skin surface (signs of blood vessel inflammation).</p><p>&middot;&nbsp;&nbsp;&nbsp; Severe upper stomach pain which spreads to the back (possible signs of pancreas inflammation).</p><p>&middot;&nbsp;&nbsp;&nbsp; Unexplained muscle weakness or pain, or dark (red-brown) urine (possible signs of muscle breakdown).</p><p><strong><u>The most common side effects are:</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp; Stomach problems such as loss of appetite, ache, indigestion, feeling bloated or sick</p><p>&middot;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp; Itching, rash or swelling</p><p>&middot;&nbsp;&nbsp;&nbsp; Pains in the muscles and joints</p><p><strong><u>The side effects listed below have also been reported</u></strong><strong>:</strong></p><p><strong>Up to 1 in 100 people have experienced</strong></p><p>Taste loss and taste disturbance. This usually disappears within several weeks after you stop taking the medicine. However, a very small number of people, (less than 1 in 10,000), have reported that the taste disturbance lasts for some time and, as a result, they go off their food and lose weight. There have also been reports of some people experiencing anxiety or symptoms of depression as a result of these taste disturbances.</p><p><strong>Up to 1 in 1,000 people have experienced </strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Feeling unwell, dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp; Numbness or tingling</p><p><strong>Up to 1 in 10,000 people have experienced</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Feeling tired</p><p>&middot;&nbsp;&nbsp;&nbsp; Decrease in the number of some blood cells. You may notice that you seem to bleed or bruise more easily than normal, or you may catch infections easily and these might be more severe than usual</p><p>&middot;&nbsp;&nbsp;&nbsp; Psoriasis like skin eruptions, or worsening of any psoriasis including a rash or eruption of small pus containing blisters</p><p>&middot;&nbsp;&nbsp;&nbsp; Vertigo</p><p>&middot;&nbsp;&nbsp;&nbsp; Hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp; Onset or worsening of a condition called lupus (a long-term illness with symptoms including skin rash and pain in the muscles and joints)</p><p><strong><u>The following have also been reported: </u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Signs of blood disorders: weakness, unusual bleeding, bruising or frequent infections.</p><p>&middot;&nbsp;&nbsp;&nbsp; Disorders of sense of smell which may be permanent, impaired hearing, hissing and/or ringing in the ears, flu like symptoms, increase in blood of a muscle enzyme called creatine phosphokinase (may be found on a blood test).</p><p><strong>If any of these side effects gets serious, or if you notice any side effect not listed in this leaflet, please tell your doctor.</strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>To report any side effect(s):</u></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax:</strong>&nbsp;+966-11-205-7662</p><p><strong>Call NPC at</strong>&nbsp;+966-11-2038222,&nbsp;<strong>Exts:</strong>&nbsp;2317-2356-2353-2354-2334-2340.</p><p><strong>Toll free phone:</strong>&nbsp;8002490000</p><p><strong>E-mail:</strong>&nbsp;npc.drug@sfda.gov.sa</p><p><strong>Website:</strong>&nbsp;www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp;&nbsp;&nbsp; Do not use <strong>Negafen</strong> after the expiry date which is stated on the carton and on the blister.</p><p>-&nbsp;&nbsp;&nbsp; Store below 30&deg;C, protected from light.</p><p>-&nbsp;&nbsp;&nbsp; Do not use <strong>Negafen</strong> if you notice any visible sign of deterioration.</p><p>-&nbsp;&nbsp;&nbsp; Medicines should not be disposed off via wastewater or household waste. Ask your pharmacist how to dispose off medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Terbinafine. Each tablet contains: Terbinafine hydrochloride equivalent to terbinafine 250mg.</p><p>Other ingredients: Hydroxypropylcellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and microcrystalline cellulose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Negafen tablets are available in packs of 14 tablets each (one blister only).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                24/06/2013
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تربينافين، المادة الفعالة في أقراص <strong>نيجافين</strong>، عبارة عن دواء مضاد للفطريات.</p><p>تستعمل أقراص <strong>نيجافين</strong> لعلاج حالات العدوى الفطرية التالية:</p><p>-&nbsp; العدوى الفطرية التي تصيب الأظافر بسبب الفطريات الجلدية (تينيا أونجويم).</p><p>العدوى الشديدة بالديدان الحلقية (تينيا كوربوريس، وتينيا كروريس، وتينيا بيديس).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>يجب عدم إعطاء أقراص نيجافين للأطفال.</strong></p><p><strong>يجب عليك عدم تناول نيجافين </strong><strong>في الحالات التالية: </strong></p><p>-&nbsp; إذا كنت تعاني من الحساسية (فرط الحساسية) تجاه تربينافين أو أي من المكونات الأخرى في هذه الأقراص (انظر البند رقم 6).</p><p>-&nbsp; إذا كنت تعاني من مشكلات حادة في الكبد أو الكلى.</p><p><strong>يجب عليك استشارة الطبيب </strong><strong>في الحالات التالية: </strong></p><p>-&nbsp; إذا كنت تعاني من داء الصدفية.</p><p>-&nbsp; إذا كنت تعاني من داء الذئبة الحمامية الجهازي.</p><p><strong>تناول الأدوية الأخرى:</strong></p><p>يرجى أن تخبر طبيبك أو الصيدلي الذي تتعامل معه إذا كنت تتناول أو تناولت مؤخراًَ أية أدوية أخرى، بما في ذلك الأدوية التي تصرف بدون وصفة طبية.</p><p>قد تؤثر بعض الأدوية الأخرى على استخدام <strong>نيجافين</strong> أو العكس بالعكس.</p><p><strong>استشر طبيبك إذا كنت تتناول أي من الأدوية التالية:</strong></p><p>&middot;&nbsp; ريفامبيسين (دواء يستخدم في علاج حالات العدوى)</p><p>&middot;&nbsp; سيميتيدين (دواء يستخدم في علاج مشكلات المعدة بالمثل عسر الهضم أو القرحة)</p><p>&middot;&nbsp; مضادات الإكتئاب بما في ذلك مضادات الإكتئاب ثلاثية الحلقات، مثبطات إعادة أخذ السيروتينين الإنتقائية أو مثبطات إنزيم أكسدة الأمين الأحادي.</p><p>&middot;&nbsp; موانع الحمل الفموية (حيث يمكن حدوث عدم انتظام للدورة الشهرية و نزيف لدى بعض المرضى من النساء)</p><p>&middot;&nbsp; غالقات مستقبلات بيتا أو مضادات اضطراب نظم القلب (أدوية تستخدم في علاج المشكلات القلبية)</p><p>&middot;&nbsp; الوارفارين (دواء يستخدم لتمييع ومنع تخثر الدم)</p><p>&middot;&nbsp; الأدوية المستخدمة في علاج المشكلات القلبية (بالمثل بروبافينون، أميودارون)</p><p>&middot;&nbsp; سايكلوسبورين، دواء يستخدم للسيطرة على الجهاز المناعي وذلك لمنع رفض الجسم للأعضاء المزروعة</p><p>&middot;&nbsp; الأدوية المستخدمة في علاج حالات العدوى التي تسببها الفطريات (بالمثل فلوكونازول، كيتوكونازول)</p><p>&middot;&nbsp; الأدوية المستخدمة في علاج السعال (بالمثل ديكستروميثورفان)</p><p>&middot;&nbsp; الكافيين</p><p>يجب عليك إجراء فحوصات الدم قبل وأثناء العلاج باستعمال <strong>نيجافين</strong> وذلك لمراقبة وظائف الكبد.</p><p><strong>الحمل والرضاعة:</strong></p><p>إذا كنت حاملاً أو تخططين لتصبحي حاملاً، فيجب عليك استشارة الطبيب قبل أن تتناولي <strong>نيجافين</strong>.</p><p>يجب عليك عدم تناول هذا الدواء إذا كنت مرضعاً حيث أن تربينافين قد يفرز في حليب الثدي.</p><p><strong>القيادة واستخدام الآلات:</strong></p><p>لقد أفاد بعض الأشخاص عن شعورهم بالدوخة أو الدوار أثناء استعمالهم <strong>نيجافين</strong>.</p><p>في حال شعورك بمثل هذه الأعراض، يجب عليك عدم القيادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سوف يقرر الطبيب مقدار الجرعة التي يجب عليك تناولها من <strong>نيجافين</strong>. يجب استعمال <strong>نيجافين </strong>دائماً<strong> </strong>بدقة وفقاً لتعليمات الطبيب. استشر الطبيب أو الصيدلي الذي تتعامل معه ما لم تكن متأكداً من طريقة الاستعمال.</p><p><strong>الجرعة الإعتيادية للبالغين، بما في ذلك كبار السن، هي 250 ملغم مرة واحدة يومياً.</strong></p><p>تعتمد مدة العلاج على نوع ومدى وشدة العدوى كما يلي:</p><p>العدوى الفطرية التي تصيب الأظافر: 250 ملغم مرة واحدة يومياً لمدة 6 أسابيع (للعدوى التي تصيب أظافر أصابع اليد) إلى 12 أسبوع (للعدوى التي تصيب أظافر أصابع القدم). إن بعض أنواع العدوى التي تصيب أظافر أصابع القدم قد تحتاج إلى فترات علاج أطول، وذلك يعتمد على مدى العدوى.</p><p>تينيا بيديس: 250 ملغم مرة واحدة يومياً لمدة 2 - 6 أسابيع.</p><p>تينيا كروريس: 250 ملغم مرة واحدة يومياً لمدة 2 - 4 أسابيع.</p><p>تينيا كوربوريس: 250 ملغم مرة واحدة يومياً لمدة 4 أسابيع.</p><p><strong><u>ملاحظات</u></strong><strong>:</strong></p><p>&middot;&nbsp; إذا كنت تعاني من خلل في وظائف الكلى، فقد يقوم الطبيب بخفض مقدار الجرعة التي تتناولها من <strong>نيجافين</strong>.</p><p>&middot;&nbsp; ابتلع الأقراص كاملة مع كوب من الماء.</p><p><strong>إذا سهوت عن تناول نيجافين:</strong></p><p>إذا سهوت عن تناول جرعة من<strong> نيجافين</strong>، فيجب عليك تناول الجرعة في أسرع وقت ممكن حال تذكرها، ثم الإستمرار في تناول بقية الجرعات التالية في أوقاتها المعتادة. لا تتناول جرعة مضاعفة لتعويض الجرعات المفردة التي قد سهوت عن تناولها.</p><p><strong>إذا تناولت نيجافين بجرعة أكبر من الاعتيادية على سبيل الخطأ:</strong></p><p>إذا تناولت <strong>نيجافين</strong> بجرعة أكبر من الاعتيادية، اتصل بطبيبك أو توجه على الفور إلى المستشفى.</p><p><strong>إذا توقفت عن تناول نيجافين:</strong></p><p>لا توقف العلاج من تلقاء نفسك. اتصل بطبيبك أو الصيدلي الذي تتعامل معه قبل إيقاف العلاج.</p><p><strong>إذا كانت لديك مزيد من الاستفسارات التي تخص استعمال هذا المستحضر، اتصل بطبيبك أو الصيدلي الذي تتعامل معه.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن جميع الأدوية، قد يؤدي <strong>نيجافين</strong><strong> </strong>إلى حدوث تأثيرات جانبية، ولكن قد لا تحدث لكل شخص.</p><p>إن أية تأثيرات جانبية قد تحدث عادة ما تكون طفيفة أو معتدلة ولا تستمر لفترة طويلة.</p><p><strong><u>بعض التأثيرات الجانبية التي قد تكون خطيرة</u></strong><strong>:</strong></p><p>توقف عن تناول <strong>نيجافين</strong> مع طلب المشورة الطبية على الفور إذا لاحظت ظهور أحد الأعراض التالية التي نادراً ما قد تحدث:</p><p>&middot;&nbsp; اصفرار الجلد أو العينين. تغير لون البول ليصبح داكناً بصورة غير معتادة أو يصبح لون البراز شاحب، شعور مستمر بالغثيان بصورة غير مبررة، مشكلات في المعدة، فقدان الشهية أو الشعور بالتعب بصورة غير معتادة أو الضعف (قد يشير ذلك إلى وجود مشكلات في الكبد)، ارتفاع مستوى إنزيمات الكبد والتي يمكن ملاحظتها في نتائج فحوصات الدم.</p><p>&middot;&nbsp; تفاعلات جلدية خطيرة بما في ذلك الطفح الجلدي، حساسية تجاه الضوء، ظهور بثور أو بعض الأمراض الجلدية الأخرى.</p><p>&middot;&nbsp; شعور بالضعف، حدوث نزيف بصورة غير معتادة، كدمات، شحوب لون الجلد بصورة غير طبيعية، شعور بالتعب بصورة غير معتادة، أو الضعف أو ضيق في التنفس عند بذل مجهود أو تكرر الإصابة بالعدوى (قد يكون ذلك علامة على وجود اضطرابات في الدم).</p><p>&middot;&nbsp; صعوبة في التنفس، دوخة، حدوث تورم بصورة رئيسية في الوجه والحلق، توهج، آلام في البطن نتيجة لحدوث بعض التقلصات، تيبس، طفح جلدي، حمى أو تورم/تضخم الغدد الليمفاوية (علامات محتملة لتفاعلات تحسسية شديدة).</p><p>&middot;&nbsp; ظهور بعض الأعراض بالمثل الطفح الجلدي، حمى، حكة، شعور بالتعب أو إذا لاحظت ظهور بقع أرجوانية اللون تحت سطح الجلد (علامات على التهاب الأوعية الدموية).</p><p>&middot;&nbsp; آلام شديدة في الجزء العلوي من المعدة والتي قد تمتد لتصل إلى الظهر (علامات محتملة لالتهاب البنكرياس).</p><p>&middot;&nbsp; ضعف العضلات بصورة غير مبررة أو شعور بالألم، أو تغير لون البول ليصبح داكناً (أحمر- بني) (علامات محتملة لتكسر العضلات).</p><p><strong><u>التأثيرات الجانبية الأكثر شيوعاً:</u></strong></p><p>&middot;&nbsp; الصداع</p><p>&middot;&nbsp; مشكلات في المعدة بالمثل فقدان الشهية، شعور بالألم، عسر الهضم، شعور بالإمتلاء أو الإعياء</p><p>&middot;&nbsp; إسهال</p><p>&middot;&nbsp; حكة، طفح جلدي أو تورم</p><p>&middot;&nbsp; آلام في العضلات والمفاصل</p><p><strong><u>كما تم تسجيل التأثيرات الجانبية المذكورة أدناه:</u></strong></p><p><strong>أصابت شخص واحد لكل 100 من الأشخاص</strong></p><p>فقدان حاسة التذوق واضطرابات في حاسة التذوق. عادة ما تختفي هذه التأثيرات خلال عدة أسابيع بعد التوقف عن تناول الدواء. ولكن مع ذلك، فقد أفاد عدد قليل جداً من الأشخاص (أقل من شخص واحد لكل 10.000 من الأشخاص) بأن الاضطرابات في حاسة التذوق قد تستمر لبعض الوقت، ونتيجة لذلك عزفوا عن تناول الطعام وفقدوا الوزن.</p><p>كما وجدت تقارير لبعض الأشخاص الذين عانوا من القلق أو أعراض الإكتئاب نتيجة تعرضهم لاضطرابات في حاسة التذوق.</p><p><strong>أصابت شخص واحد لكل 1000 من الأشخاص</strong></p><p>&middot;&nbsp; &nbsp;شعور بتوعك ودوخة</p><p>&middot;&nbsp; شعور بالخدر أو بالوخز</p><p><strong>أصابت شخص واحد لكل 10.000 من الأشخاص</strong></p><p>&middot;&nbsp; شعور بالتعب</p><p>&middot;&nbsp; نقص عدد خلايا الدم. قد تلاحظ أنك أصبحت عرضة لحدوث النزيف أو الكدمات بصورة أسهل من المعتادة، أو أنك قد تصاب بالعدوى بسهولة، والتي قد تكون أكثر حدة من المعتاد عليه.</p><p>&middot;&nbsp; الصدفية المشابهه للطفح الجلدي، أو تفاقم أي شكل من أشكال الصدفية بما في ذلك الطفح الجلدي أو انتشار ال<em>بثور الصديدية</em></p><p>&middot;&nbsp; فقدان الشعر</p><p>&middot;&nbsp; ظهور أو تفاقم الحالة المرضية التي تعرف باسم مرض الذئبة (مرض طويل الأمد تصاحبه عدة أعراض من ضمنها الطفح الجلدي وآلام في العضلات والمفاصل)</p><p><strong><u>كما تم أيضاً تسجيل ما يلي: </u></strong></p><p>&middot;&nbsp; علامات لاضطرابات الدم: شعور بالضعف، حدوث نزيف غير معتاد، كدمات أو تكرر الإصابة بالعدوى.</p><p>&middot;&nbsp; اضطرابات في حاسة الشم والتي قد تدوم، ضعف حاسة السمع، صفير و/أو رنين في الأذنين، أعراض تشبه الانفلونزا، ارتفاع مستوى إنزيم العضلات في الدم المعروف باسم كرياتنين فوسفوكاينيز (يمكن ظهور ذلك في فحوصات الدم).</p><p><strong>في </strong><strong>حال زيادة حدة الأعراض الجانبية</strong><strong> </strong><strong>أو إذا لاحظت حدوث تأثيرات جانبية أخرى لم تذكر في هذه النشرة، يرجى إخبار طبيبك أو الصيدلي الذي تتعامل معه.</strong><strong> </strong></p><p><strong><u>للإبلاغ عن حدوث أية تأثيرات جانبية</u></strong><strong><u>:</u></strong></p><p><strong>&nbsp;</strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p><strong>رقم الفاكس: 7662-205-11-966</strong><strong>+</strong></p><p><strong>يرجى الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية على: 2038222-11-966+</strong></p><p><strong>وصلة هاتف:2340-2334-2354-2353-2356-2317</strong></p><p><strong>الهاتف المجاني: 8002490000</strong></p><p><strong>البريد الإلكتروني: </strong><strong>npc.drug@sfda.gov.sa</strong></p><p><strong>الموقع الإلكتروني: www.sfda.gov.sa/npc</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-&nbsp;&nbsp;&nbsp;&nbsp; تحفظ بعيداً عن متناول ومرأى الأطفال.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم <strong>نيجافين</strong> بعد تاريخ انتهاء الصلاحية المذكور على العلبة والشريط.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; تحفظ في درجة حرارة أقل من 30&ordm;م، بعيداً عن الضوء.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم <strong>نيجافين</strong> إذا لاحظت وجود علامات تلف واضحة.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي تربينافين.</p><p>يحتوي كل قرص على هيدروكلوريد التربينافين بما يعادل تربينافين 250 ملغم.</p><p>مواد أخرى: هيدروكسي بروبيل سليلوز، كروس كارميلوز الصوديوم، ثنائي أكسيد السيليكون الغروي، استيارات المغنيسيوم وسليلوز دقيق البلورات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            تتوفر أقراص نيجافين في عبوات تحتوي كل منها على 14 قرصاً (شريط واحد فقط). 
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&quot;الخليج للصناعات الدوائية &quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            24-06-2013
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Negafen 250mg Tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains:
	
Item no.	Materials Name	                      Scale
                  (mg/tablet)
	Active Ingredients:
	
1.		Terbinafine Hydrochloride equivalent to Terbinafine	                 282.00
                 250.00
	Inactive Ingredients:	
1.		Hydroxypropylcellulose 	                    8.00
2.		Croscarmellose sodium	                  12.00
3.		Colloidal silicon dioxide	                    1.20
4.		Magnesium stearate	                   2. 00
5.		Microcrystalline cellulose	        q.s  to 420.00
6.		Purified Water	                 q.s  














Note:

      The variation in quantity of Terbinafine Hydrochloride due to assay will be adjusted by microcrystalline cellulose.
   Evaporates during drying Process.
q.s = quantity sufficient.
For a full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets 

Description:
White to off white, round, bevel, biconvex tablets.
Marking:
Face one: Embossed “NEGAFEN 250”
Face two: Break line.	



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fungal infections of the skin and nails caused by <em>Trichophyton</em> (eg. <em>T. rubrum</em>, <em>T.mentagrophytes, T. verrucosum, T. violaceum</em>), <em>Microsporum canis </em>and <em>Epidermophyton floccosum</em>.</p><p>1. &nbsp;&nbsp;Oral terbinafine is indicated in the treatment of ringworm (tinea corporis, tinea cruris and tinea pedis) where oral therapy is considered appropriate due to the site, severity or extent of the infection.</p><p>2. &nbsp;&nbsp;Oral terbinafine is indicated in the treatment of onychomycosis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adults</u></p><p>250mg once daily.</p><p>The duration of treatment varies according to the indication and the severity of the infection.</p><p><em><u>Skin infections</u></em></p><p>Likely durations of treatment are as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:80%"><tbody><tr><td style="vertical-align:top"><p>Tinea pedis (interdigital, plantar/moccasin type):</p></td><td style="vertical-align:top"><p>2 to 6 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Tinea corporis:</p></td><td style="vertical-align:top"><p>4 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Tinea cruris:</p></td><td style="vertical-align:top"><p>2 to 4 weeks</p></td></tr></tbody></table><p><em><u>Onychomycosis</u></em></p><p>The duration of treatment for most patients is between 6 weeks and 3 months. Treatment periods of less than 3 months can be anticipated in patients with fingernail infection, toenail infection other than of the big toe, or patients of younger age. In the treatment of toenail infections, 3 months is usually sufficient although a few patients may require treatment of 6 months or longer. Poor nail outgrowth during the first weeks of treatment may enable identification of those patients in whom longer therapy is required.</p><p>Complete resolution of the signs and symptoms of infection may not occur until several weeks after mycological cure.</p><p><strong><u>Additional information on special population</u></strong></p><p><strong>Liver impairment</strong></p><p>Terbinafine is not recommended for patients with chronic or active liver disease (see section 4.4 Special warnings and precautions for use).</p><p><em><u>&nbsp;</u></em></p><p><em><u>&nbsp;</u></em></p><p><strong>Renal impairment</strong></p><p>The use of terbinafine has not been adequately studied in patients with renal impairment and is therefore not recommended in this population (see section 4.4 Special warnings and precautions for use and section 5.2 Pharmacokinetic properties).</p><p><strong>Children</strong></p><p>A review of safety experience with oral terbinafine in children, which includes<br />314 patients involved in the UK terbinafine Post Marketing Surveillance study, has shown that the adverse event profile in children is similar to that seen in adults. No evidence of any new, unusual or more severe reactions to those seen in the adult population have been noted. However, as data is still limited its use is not recommended.</p><p><strong>Elderly</strong></p><p>There is no evidence to suggest that elderly patients require different dosages or experience side-effects different to those of younger patients. The possibility of impairment of liver or kidney function should be considered in this age group (see Precautions).</p><p><strong><u>Method of administration</u></strong></p><p>Via the oral route.</p><p>&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to terbinafine or to any of the excipients of Negafen tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Liver Function</u></strong></p><p>Terbinafine is not recommended for patients with chronic or active liver disease. Before prescribing <strong>Negafen</strong> tablets, any pre-existing liver disease should be assessed.</p><p>Hepatotoxicity may occur in patients with and without pre-existing liver disease therefore periodic monitoring (after 4 - 6 weeks of treatment) of liver function test is recommended. <strong>Negafen</strong> tablets should be immediately discontinued in case of elevation of liver function test.</p><p>Very rare cases of serious liver failure (some with a fatal outcome, or requiring liver transplant) have been reported in patients treated with terbinafine. In the majority of liver failure cases the patients had serious underlying systemic conditions and a causal association with the intake of terbinafine was uncertain (see section 4.8 Undesirable effects).</p><p>Patients prescribed <strong>Negafen</strong> tablets should be instructed to report immediately any signs or symptoms suggestive of liver dysfunction such as pruritus, unexplained persistent nausea, decreased appetite, anorexia, jaundice, vomiting, fatigue, right upper abdominal pain, dark urine, or pale stools. Patients with these symptoms should discontinue taking oral terbinafine and the patient&#39;s liver function should be immediately evaluated.</p><p><strong>&nbsp;</strong></p><p><em><u>&nbsp;</u></em></p><p><strong><u>Dermatological effects</u></strong></p><p>Serious skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis) have been very rarely reported in patients taking terbinafine. If progressive skin rash occurs, <strong>Negafen</strong> tablets treatment should be discontinued.</p><p>Terbinafine should be used with caution in patients with pre-existing psoriasis, as very rare cases of exacerbation of psoriasis have been reported.<strong> </strong></p><p><strong><u>Haematological effects</u></strong></p><p>Very rare cases of blood dyscrasias (neutropenia, agranulocytosis, thrombocytopenia, pancytopenia) have been reported in patients treated with terbinafine. Aetiology of any blood dyscrasias that occur in patients treated with terbinafine should be evaluated and consideration should be given for a possible change in medication regimen, including discontinuation of treatment with <strong>Negafen</strong> tablets.</p><p><strong><u>Renal function</u></strong></p><p>In patients with renal impairment (creatinine clearance less than 50 mL/min or serum creatinine of more than 300 micro mol/L) the use of terbinafine has not been adequately studied, and therefore, is not recommended (see section 5.2 Pharmacokinetic properties).</p><p><strong><u>Other</u></strong></p><p>Terbinafine should be used with caution in patients with lupus erythematosus as very rare cases of lupus erythematosus have been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Effect of other medicinal products on terbinafine</u></strong></p><p>The plasma clearance of terbinafine may be accelerated by drugs which induce metabolism and may be inhibited by drugs which inhibit cytochrome P450.<br />Where co-administration of such agents is necessary, the dosage of terbinafine may need to be adjusted accordingly.</p><p><em>The following medicinal products may increase the effect or plasma concentration of terbinafine: </em></p><p>Cimetidine decreased the clearance of terbinafine by 30%.</p><p>Fluconazole increased the Cmax and AUC of terbinafine by 52% and 69% respectively, due to inhibition of both CYP2C9 and CYP3A4 enzymes.</p><p>Similar increase in exposure may occur when other drugs which inhibit both CYP2C9 and CYP3A4 such as ketoconazole and amiodarone are concomitantly administered with terbinafine.</p><p><em>&nbsp;</em></p><p><em>The following medicinal products may decrease the effect or plasma concentration of terbinafine: </em></p><p>&nbsp;</p><p>Rifampicin increased the clearance of terbinafine by 100%.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Effect of terbinafine on other medicinal products</u></strong></p><p>Studies undertaken in vitro and in healthy volunteers suggest that terbinafine shows negligible potential to inhibit or induce the clearance of drugs that are metabolised via other cytochrome P450 enzymes (e.g. tolbutamine, terfenadine, triazolam, oral contraceptives) with exception of those metabolised through CYP2D6 (see below).</p><p>Terbinafine does not interfere with the clearance of antipyrine or digoxin.</p><p>There was no effect of terbinafine on the pharmacokinetics of fluconazole. Further there was no clinically relevant interaction between terbinafine and the potential comedications cotrimoxazole (trimethoprim and sulfamethoxazole), zidovudine or theophylline.</p><p>Some cases of menstrual disturbance (breakthrough bleeding and irregular cycle) have been reported in patients taking terbinafine concomitantly with oral contraceptives, although the incidence of these disorders remains within the background incidence of patients taking oral contraceptives alone.</p><p><em>Terbinafine may increase the effect or plasma concentration of the following medicinal products: </em></p><p>Caffeine &ndash; Terbinafine decreased the clearance of caffeine administered intravenously by 21%.</p><p>Compounds predominantly metabolised by CYP2D6 &ndash; In vitro and in vivo studies have shown that terbinafine inhibits the CYP2D6-mediated metabolism. This finding may be of clinical relevance for patients receiving compounds predominantly metabolised by CYP2D6, e.g. certain members of the following drug classes, tricyclic antidepressants (TCA&#39;s), &beta;-blockers, selective serotonin reuptake inhibitors (SSRIs), antiarrhythmics (including class 1A, 1B and 1C) and monoamine oxidase inhibitors (MAO-Is) Type B, especially if they also have a narrow therapeutic window (see section 4.4).</p><p>Terbinafine decreased the clearance of desipramine by 82%.</p><p>In studies in healthy subjects characterized as extensive metabolisers of dextromethorphan (antitussive drug and CYP2D6 probe substrate), terbinafine increased the dextromethorphan/dextrorphan metabolic ratio in urine by 16- to 97-fold on average. Thus, terbinafine may convert extensive CYP2D6 metabolisers to poor metaboliser status.</p><p><em>Terbinafine may decrease the effect or plasma concentration of the following medicinal products: </em></p><p>Terbinafine increased the clearance of ciclosporin by 15%.</p><p>&nbsp;</p><p>Rare cases of changes in INR and/or prothrombin time have been reported in patients receiving terbinafine concomitantly with warfarin.</p><p>&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>Foetal toxicity and fertility studies in animals suggest no adverse effects.</p><p>Since clinical experience in pregnant women is very limited, terbinafine tablets should not be used during pregnancy unless clinical condition of the woman requires treatment with oral terbinafine and the potential benefits for the mother outweigh any potential risks for the foetus.</p><p><strong><u>Lactation</u></strong></p><p>Terbinafine is excreted in breast milk and therefore mothers should not receive terbinafine treatment whilst breast-feeding.</p><p><strong><u>Fertility</u></strong></p><p>Foetal toxicity and fertility studies in animals suggest no adverse effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of terbinafine treatment on the ability to drive and use machines have been performed. Patients who experience dizziness as an undesirable effect should avoid driving vehicles or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Side effects are generally mild to moderate, and transient. The following adverse reactions have been observed in the clinical trials or during post-marketing experience.</p><p>Adverse reactions are ranked under headings of frequency, using the following convention:</p><p>Very common (&ge; 1/10); Common (&ge; 1/100, &lt; 1/10); Uncommon (&ge; 1/1,000, &lt; 1/100); Rare (&ge; 1/10,000, &lt; 1/1,000); Very rare (&lt; 1/10,000), Not known (frequency cannot be estimated from available data) including isolated reports.</p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td colspan="2"><p><strong>Blood and lymphatic system disorders </strong></p></td></tr><tr><td><p>Very rare</p></td><td><p>Neutropenia, agranulocytosis, thrombocytopenia.</p></td></tr><tr><td><p>Not known</p></td><td><p>Anaemia, Pancytopenia</p></td></tr><tr><td colspan="2"><p><strong>Immune system disorders </strong></p></td></tr><tr><td><p>Very rare</p></td><td><p>Anaphylactoid reactions (including angioedema), cutaneous and systemic lupus erythematosus.</p></td></tr><tr><td><p>Not known</p></td><td><p>Anaphylactic reaction, serum sickness-like reaction.</p></td></tr><tr><td colspan="2"><p><strong>&nbsp;</strong></p><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td><p>Very common</p></td><td><p>Decreased appetite.</p></td></tr><tr><td colspan="2"><p><strong>Psychiatric disorders </strong></p></td></tr><tr><td><p>Not known</p></td><td><p>Anxiety and depressive symptoms secondary to taste disturbances</p></td></tr><tr><td colspan="2"><p><strong>Nervous system disorders </strong></p></td></tr><tr><td><p>Common</p></td><td><p>Headache.</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Taste disturbances, including taste loss, which usually recover within several weeks after discontinuation of the drug. Isolated cases of prolonged taste disturbance have been reported, sometimes leading to a decrease of food intake and significant weight loss.</p></td></tr><tr><td><p>Rare</p></td><td><p>Paraesthesia, hypoaesthesia, dizziness.</p></td></tr><tr><td><p>Not known</p></td><td><p>Anosmia including permanent anosmia, hyposmia.</p></td></tr><tr><td colspan="2"><p><strong>Ear and labyrinth disorders </strong></p></td></tr><tr><td><p>Very rare</p></td><td><p>Vertigo.</p></td></tr><tr><td><p>Not known</p></td><td><p>Hypoacusis, impaired hearing, tinnitus.</p></td></tr><tr><td colspan="2"><p><strong>Vascular disorders</strong></p></td></tr><tr><td><p>Not known</p></td><td><p>Vasculitis</p></td></tr><tr><td colspan="2"><p><strong>Gastrointestinal disorders </strong></p></td></tr><tr><td><p>Very common</p></td><td><p>Gastrointestinal symptoms (feeling of fullness abdominal distension, dyspepsia, nausea, abdominal pain, diarrhoea).</p></td></tr><tr><td><p>Not known</p></td><td><p>Pancreatitis.</p></td></tr><tr><td colspan="2"><p><strong>Hepatobiliary disorders </strong></p></td></tr><tr><td><p>Rare</p></td><td><p>Cases of serious hepatic dysfunction, including hepatic failure, hepatic enzymes increased, jaundice, cholestasis and hepatitis. If hepatic dysfunction develops, treatment with terbinafine should be discontinued (see also Section 4.4).</p><p>&nbsp;</p><p>Very rare cases of serious liver failure have been reported (some with a fatal outcome, or requiring liver transplant). In the majority of liver failure cases the patients had serious underlying systemic conditions and a causal association with the intake of terbinafine was uncertain.</p></td></tr><tr><td colspan="2"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td></tr><tr><td><p>Very common</p></td><td><p>Non-serious forms of skin reactions (rash, urticaria).</p></td></tr><tr><td><p>Very rare</p></td><td><p>Serious skin reactions (e.g. Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis).</p><p>Photosensitivity (e.g. photodermatosis, photosensitivity allergic reaction and polymorphic light eruption).</p><p>Alopecia</p><p>If progressive skin rash occurs, terbinafine treatment should be discontinued.</p></td></tr><tr><td><p>Not known</p></td><td><p>Psoriasiform eruptions or exacerbation of psoriasis. Serious skin reactions (e.g. acute generalized exanthematous pustulosis (AGEP)).</p></td></tr><tr><td colspan="2"><p><strong>Musculoskeletal and connective tissue disorders </strong></p></td></tr><tr><td><p>Very common</p></td><td><p>Musculoskeletal reactions (arthralgia, myalgia).</p></td></tr><tr><td><p>Not known</p></td><td><p>Rhabdomyolysis.</p></td></tr><tr><td colspan="2"><p><strong>General disorders </strong></p></td></tr><tr><td><p>Rare</p></td><td><p>Malaise.</p></td></tr><tr><td><p>Not known</p></td><td><p>Fatigue.</p><p>Influenza-like illness, pyrexia.</p></td></tr><tr><td colspan="2"><p><strong>Investigations</strong>&nbsp;</p></td></tr><tr><td><p>Not known</p></td><td><p>Blood creatine phosphokinase increased.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A few cases of overdose (up to 5g) have been reported, giving rise to headache, nausea, upper abdominal pain and dizziness.</p><p>&nbsp;<br />The recommended treatment of overdosage consists of eliminating the drug, primarily by the administration of activated charcoal, and giving symptomatic supportive therapy if needed.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Oral antifungal agent (ATC code D01B A02).</p><p>Terbinafine is an allylamine which has a broad spectrum of antifungal activity. At low concentrations terbinafine is fungicidal against dermatophytes, moulds and certain dimorphic fungi. The activity versus yeasts is fungicidal or fungistatic depending on the species.</p><p>Terbinafine interferes specifically with fungal sterol biosynthesis at an early step. This leads to a deficiency in ergosterol and to an intracellular accumulation of squalene, resulting in fungal cell death.</p><p>Terbinafine acts by inhibition of squalene epoxidase in the fungal cell membrane. The enzyme squalene epoxidase is not linked to the cytochrome P450 system.</p><p>When given orally, the drug concentrates in skin at levels associated with fungicidal activity.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following oral administration, terbinafine is well absorbed (&gt;70%) and the absolute bioavailability of terbinafine tablets as a result of first-pass metabolism is approximately 50%.</p><p>A single oral dose of 250mg terbinafine resulted in mean peak plasma concentrations of 1.30&mu;g/ml within 1.5 hours after administration. At steady-state, in comparison to a single dose, peak concentration of terbinafine was on average 25% higher and plasma AUC increased by a factor of 2.3. From the increase in plasma AUC an effective half-life of ~30 hours can be calculated. The bioavailability of terbinafine is moderately affected by food (increase in the AUC of less than 20%), but not sufficiently to require dose adjustments.</p><p>Terbinafine binds strongly to plasma proteins. It rapidly diffuses through the dermis and concentrates in the lipophilic stratum corneum. Terbinafine is also secreted in sebum, thus achieving high concentrations in hair follicles, hair and sebum rich skins. There is also evidence that terbinafine is distributed into the nail plate within the first few weeks of commencing therapy.</p><p>Terbinafine is metabolised rapidly and extensively by at least seven CYP isoenzymes with major contributions from CYP2C9, CYP1A2, CYP3A4, CYP2C8 and CYP2C19. Biotransformation results in metabolites with no antifungal activity, which are excreted predominantly in the urine.</p><p>&nbsp;</p><p>No clinically-relevant age-dependent changes in pharmacokinetics have been observed but the elimination rate may be reduced in patients with renal or hepatic impairment, resulting in higher blood levels of terbinafine.</p><p>Single dose pharmacokinetic studies in patients with renal impairment (creatinine clearance &lt;50 ml/min) or with pre-existing liver disease have shown that clearance of terbinafine may be reduced by about 50%.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In long-term studies (up to 1 year) in rats and dogs no marked toxic effects were seen in either species up to oral doses of about 100mg/kg a day. At high oral doses, the liver and possibly also the kidneys were identified as potential target organs.</p><p>In a two-year oral carcinogenicity study in mice, no neoplastic or other abnormal findings attributable to treatment were made up to doses of 130 (males) and 156 (females) mg/kg a day. In a two-year oral carcinogenicity study in rats, an increased incidence of liver tumours was observed in males at the highest dosage level of 69mg/kg a day. The changes which may be associated with peroxisome proliferation have been shown to be species-specific since they were not seen in the carcinogenicity study in mice, dogs or monkeys.</p><p>During high-dose studies in monkeys, refractile irregularities were observed in the retina at the higher doses (non-toxic effect level 50mg/kg). These irregularities were associated with the presence of a terbinafine metabolite in ocular tissue and disappeared after drug discontinuation. They were not associated with histological changes.</p><p>A standard battery of <em>in vitro</em> and <em>in vivo</em> genotoxicity tests revealed no evidence of mutagenic or clastogenic potential.</p><p>No adverse effects on fertility or other reproduction parameters were observed in studies in rats or rabbits. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect; Hydroxypropylcellulose</p><p>&sect; Croscarmellose sodium</p><p>&sect; Colloidal silicon dioxide</p><p>&sect; Magnesium stearate</p><p>&sect; Microcrystalline cellulose</p><p>&sect; Purified Water</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C, protected from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>14&rsquo;s Tablets in an Alu-PVC/PVDC blister strip.</p><p>1 Blister strip packed in a printed box along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong>Keep out of the reach and sight of children.</p><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong>Medicines should not be disposed off via wastewater or household waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street.
Ras Al Khaimah - United Arab Emirates.
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05-May-2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>